Sangamo Presents Data from In Vivo Protein Replacement Platform at ASH
December 10, 2013 at 07:18 AM EST
Sangamo BioSciences (Nasdaq: SGMO ) announced the presentation of new pre-clinical data demonstrating therapeutic levels of gene modification in non-human primates (NHPs) from its In Vivo Protein Replacement Platform. Based on Sangamo's zinc finger DNA-binding protein (ZFP) genome-editing technology, the platform enables the permanent production of therapeutic proteins from